Eugenosedin-A prevents hyperglycaemia, hyperlipidaemia and lipid peroxidation in C57BL/6J mice fed a high-fat diet

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 4, 2009, Pages 517-525

  Shen, Kuo Ping ^a   Lin, Hui Li ^a   Hsieh, Su Ling ^b   Kwan, Aij Lie ^b   Chen, Ing Jun ^c   Wu, Bin Nan ^c  

^a MEIHO UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

High density lipoprotein (LDL) receptor; HMG CoA reductase; Hyperglycaemia; Hyperlipidaemia; Lipogenesis genes

Indexed keywords

ATORVASTATIN; COENZYME A; EUGENOSEDIN A; FREE RADICAL; GLUCOSE; GLUTATHIONE PEROXIDASE; INSULIN; KETANSERIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MALONALDEHYDE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRAZOSIN; PROPRANOLOL; SEROTONIN ANTAGONIST; STEROL REGULATORY ELEMENT BINDING PROTEIN 1A; UNCLASSIFIED DRUG; EUGENOSEDIN-A; HEPTANOIC ACID DERIVATIVE; PIPERAZINE DERIVATIVE; PYRROLE DERIVATIVE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BRAIN; C57BL 6 MOUSE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HOMEOSTASIS; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID DIET; LIPID METABOLISM; LIPID PEROXIDATION; LIPOGENESIS; MOUSE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; TREATMENT DURATION; WEIGHT GAIN; ADIPOSE TISSUE; ANIMAL; BLOOD; C57BL MOUSE; DRUG EFFECT; FAT INTAKE; GENETICS; LIVER; METABOLISM;

ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; BRAIN; DIETARY FATS; FEMALE; GLUTATHIONE PEROXIDASE; HEPTANOIC ACIDS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; INSULIN; KETANSERIN; LIPID PEROXIDATION; LIPOGENESIS; LIVER; MALONDIALDEHYDE; MICE; MICE, INBRED C57BL; PIPERAZINES; PPAR GAMMA; PRAZOSIN; PROPRANOLOL; PYRROLES; SUPEROXIDE DISMUTASE; WEIGHT GAIN;

EID: 85047684550     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.04.0015     Document Type: Article

References (47)

1. Astrup A. Healthy lifestyles in Europe: preventing of obesity and type II diabetes by diet and physical activity. Public Health Nutr 2001; 4: 499-515.
2. Lebovitz HE. Insulin resistance and consequence. Exp Clin Endocrinol Diabetes 2001; 109: 135-148.
3. Park SH et al. Euonymus alatus prevents the hyperglycemia and hyperlipidemia induced by high-fat diet in ICR mice. J Ethnopharmacol 2005; 102: 326-335.
4. Nakamora K et al. Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans. Blood Coagul Fibrinolysis 2001; 12: 391-397.
5. Aviram M et al. Serotonin increases macrophage uptake of oxidized low density lipoprotein. Eur J Clin Chem Clin Biochem 1992; 30: 55-61.
6. Suguro T et al. Serotonin acts as an up-regulator of acylcoenzyme A : cholesterol acyltransferase-1 in human monocyte-macrophages. Atherosclerosis 1992; 186: 275-281.
7. Monmany J et al. Effects of long-term treatment with metoprolol and hydrochlorothiazide on plasma lipids and lipoproteins. J Intern Med 1990; 228: 323-331.
8. Lichtlen PR et al. Retardation of angiographic progression of coronary artery disease by nifedipine: results of the international nifedipine trial on antiatherosclerotic therapy. Lancet 1990; 335: 1109-1113.
9. Avci G et al. Antihypercholesterolaemic and antioxidant activity assessment of some plants used as remedy in Turkish folk medicine. J Ethnopharmacol 2006; 107: 418-423.
10. Esterbauer H et al. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992; 13: 341-390.
11. Shen KP et al. Hypotensive effects of eugenosedin-A with serotonin, alpha- and beta-adrenoceptor antagonistic activities in spontaneously hypertensive and normotensive rats. Pharmacology 2004; 71: 91-101.
12. Shen KP et al. Eugenosedin-A amelioration of lipopolysaccharide- induced up-regulation of p38 MAPK, inducible nitric oxide synthase and cyclooxygenase-2. J Pharm Pharmacol 2007; 59: 879-889.
13. Ishida T et al. Seortonin-induced hypercontraction through 5-hydroxytryptamine 1B receptors in atherosclerotic rabbit coronary arteries. Circulation 2001; 103: 1289-1295.
14. 2A antagonist, retards the progression of atherosclerosis through a novel mechanism. Atherosclerosis 2003; 168: 23-31.
15. Shen KP et al. Antioxidant eugenosedin-A protects against lipopolysaccharide-induced hypotension, hyperglycaemia and cytokine immunoreactivity in rats and mice. J Pharm Pharmacol 2005; 57: 117-125.
16. Yun SN et al. Wild ginseng prevents the onset of high-fat diet induced hyperglycemia and obesity in ICR mice. Arch Pharm Res 2006; 27: 790-796.
17. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-372.
18. Lam DD, Heisler LK. Serotonin and energy balance: molecular mechanisms and implications for type 2 diabetes. Expert Rev Mol Med 2007; 9: 1-24.
19. 2A receptor inactivation in obese Ay mice. Biochem Biophys Res Commun 2006; 351: 1078-1082.
20. Ueshiba H, Miyachi Y. Effect of doxazosin on insulin resistance in hypertensive patients with obesity. Horm Metab Res 2003; 35: 532-536.
21. Abdel-Zaher AO et al. The potential antidiabetic activity of some alpha-2 adrenoceptor antagonists. Pharmacol Res 2001; 44: 397-409.
22. Rashid S et al. Beta-blockade, but not normoglycemia or hyperinsulinemia, markedly diminishes stress-induced hyperglycemia in diabetic dogs. Diabetes 2000; 49: 253-262.
23. Bhatt P et al. Comparative effectiveness of carvedilol and propranolol on glycemic control and insulin resistance associated with L-thyroxin-induced hyperthyroidism - an experimental study. Can J Physiol Pharmacol 2007; 85: 514-520.
24. Inoue T, Node K. Statin therapy for vascular failure. Cardiovasc Drugs Ther 2007; 21: 281-295.
25. Loschiavo C et al. Effects of ketanserin administration on lipid metabolism and platelet aggregation in hypertensive patients. Int J Clin Pharmacol Ther Toxicol 1990; 28: 455-457.
26. Ahaneku JE et al. Changes in lipid and lipoprotein values during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients. J Pak Med Assoc 1994; 44: 166-169.
27. Baymiller SP et al. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent betaadrenergic antagonist treatment. Schizophr Res 2003; 59: 49-57.
28. MangalogluL et al. Treatmentwith atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animalmodel of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity. Metabolism 2002; 51: 409-418.
29. Suzuki M et al. Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice. J Atheroscler Thromb 2005; 12: 77-84.
30. Foufelle F, Ferre P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J 2002; 366: 377-391.
31. Marseille-Tremblay C et al. Effect of an enriched cholesterol diet during gestation on fatty acid synthase, HMG-CoA reductase and SREBP-1/2 expressions in rabbits. Life Sci 2007; 81: 772-778.
32. Chu K et al. Stearoyl-coenzyme A desaturase 1 deficiency protects against hypertriglyceridemia and increases plasma high-density lipoprotein cholesterol induced by liver X receptor activation. Mol Cell Biol 2006; 26: 6786-6798.
33. Brown MS, Goldstein JL. Receptor-mediated endocytosis: insight from the lipoprotein receptor system. Proc Natl Acad Sci USA 1979; 76: 3330-3337.
34. Lijnen P et al. Serum cholesterol during ketanserin and propranolol administration in hypertensive patients. J Cardiovasc Pharmacol 1987; 10: 647-650.
35. Suzukawa M, Nakamura H. Effects of ketanserin on HMG-CoA reductase activity in cultured human skin fibroblasts. Cardiovasc Drug Ther 1990; 4: 67-70.
36. D'Eletto RD, Javitt NB. Effect of doxazosin on cholesterol synthesis in cell culture. J Cardiovasc Pharmacol 1989; 13(Suppl 20): 1-4.
37. Ness GC et al. Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity. J Lipid Res 1998; 39: 75-84.
38. Ness GC et al. Inhibitors of cholesterol biosynthesis increase hepatic low density lipoprotein receptor protein degradation. Arch Biochem Biophys 1996; 325: 242-248.
39. Aviram M. Platelet secretory products enhance LDL receptor activity and inhibit scavenger receptor activity in human monocyte derived macrophages. Metabolism 1989; 38: 425-430.
40. Siddiqui AM et al. The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-g. Crit Care Med 2006; 34: 1874-1882.
41. Ito M et al. Development of nonalcoholic steatohepatitis model through combination of high-fat diet and tetracycline with morbid obesity in mice. Hepatol Res 2006; 34: 92-98.
42. Mutaf I et al. Amlodipine and glutathione cycle in hypercholesterolaemia. Acta Cardiol 2004; 59: 485-492.
43. Yilmaz MI et al. Effects of statins on oxidative stress. Biol Trace Elem Res 2004; 98: 119-127.
44. Jeon SM et al. Antioxidative activity of naringin and lovastatin in high cholesterol-fed rabbits. Life Sci 2001; 69: 2855-2866.
45. Capela JP et al. Ecstasy induces apoptosis via 5-HT2A-receptor stimulation in cortical neurons. Neurotoxicology 2007; 28: 868-875.
46. Khaper N, Singal PK. Effects of afterload-reducing drugs on pathogenesis of antioxidant changes and congestive heart failure in rats. J Am Coll Cardiol 1997; 29: 856-861.
47. Alov P et al. In vitro effects of calcium channel blockers and beta-adrenergic blocking agents on microsomal lipid peroxidation and cytochrome p-450 content. Exp Toxicol Pathol 1999; 51: 277-281.